Cancer Highlights of 2009 1) Biggest Biotech Deal To-DateAfter an eight-month battle, Roche finally gained control of its longtime U.S.-biotech partner Genentech in a $46.8 billion takeover deal to reinforce its leading position in cancer medicines. Genentech’s board and shareholders ultimately accepted the Swiss drug maker’s offer of $95 a share for the 44 percent [...]
No Magic Bullets for Drug Price Reform:Notes from ASH and SABCS By Neil Canavan ASH: The High Cost of an Unmet NeedAndrew Pollack, a journalist from the New York Times, set the 2009 ASH in motion with his front-page, opening-day article, “A Fortune to Fight Cancer”, which highlighted the record-setting price of Folotyn. Approved in [...]
OBR green is our dynamic, eco-friendly companion to our print journal Oncology Business Review. Register to begin receiving OBR green today. View the Most Recent Issue»
